An efficient HPLC method for the quantitative determination of atazanavir in human plasma suitable for bioequivalence and pharmacokinetic studies in healthy human subjects

Journal of Pharmaceutical and Biomedical Analysis

Volumn 53, Issue 1, 2010, Pages 113-118

  Müller, Adrienne C ^a   Kanfer, Isadore ^a  

^a RHODES UNIVERSITY   (South Africa)

Author keywords

Atazanavir; Bioequivalence studies; Healthy human subjects; HPLC UV; Plasma

Indexed keywords

ACETIC ACID ETHYL ESTER; ACETONITRILE; AMMONIUM FORMATE; ATAZANAVIR; BUFFER; DIAZEPAM; HEXANE; NITROGEN; SODIUM CARBONATE; SOLVENT;

ACCURACY; ARTICLE; BIOEQUIVALENCE; BLOOD SAMPLING; BLOOD STORAGE; CONTROLLED STUDY; CORRELATION COEFFICIENT; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DETERMINATION; ENVIRONMENTAL TEMPERATURE; EVAPORATION; FLOW RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIQUID LIQUID EXTRACTION; NORMAL HUMAN; PH; PRIORITY JOURNAL; QUALITY CONTROL; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; TEMPERATURE; TIME;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG STABILITY; DRUG STORAGE; HIV PROTEASE INHIBITORS; HUMANS; LIMIT OF DETECTION; OLIGOPEPTIDES; PYRIDINES; SPECTROPHOTOMETRY, ULTRAVIOLET; THERAPEUTIC EQUIVALENCY;

EID: 77952322980     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2010.03.019     Document Type: Article

References (32)

1. Harrison T.S., Scott L.J. Atazanavir-a review of its use in the management of HIV infection. Drugs 2005, 65:2309-2336.
2. Goldsmith D.R., Perry C.M. Atazanavir. Drugs 2003, 63:1679-1693.
3. Busti A.J., Hall R.G., Margolis D.M. Atazanavir for the treatment of human immunodeficiency virus infection. Pharmacotherapy 2004, 24:1732-1747.
4. Molto J., Santos J.R., Valle M., Miranda C., Miranda J., Blanco A., Negredo E., Clotet B. Monitoring atazanavir concentrations with boosted or unboosted regimens in HIV-infected patients in routine clinical practice. Ther. Drug Monit. 2007, 29:648-651.
5. Martin D.E., Galbraith H., Schettler J., Ellis C., Doto J. Pharmacokinetic properties tolerability of bevirimat and atazanavir in healthy volunteers: an open-label, parallel-group study. Clin. Ther. 2008, 30:1794-1805.
6. Krishna G., Moton A., Ma L., Martinho M., Seiberling M., McLeod J. Effects of oral posaconazole on the pharmacokinetics of atazanavir alone and with ritonavir or with efavirenz in healthy adult volunteers. JAIDS 2009, 51:437-444.
7. Cateau E., Tournier N., Dupuis A., Le Moal G., Venisse N. Determination of atazanavir in human plasma using solid-phase extraction and high-performance liquid chromatography. J. Pharm. Biomed. Anal. 2005, 39:791-795.
8. Cattaneo D., Maggiolo F., Ripamonti D., Perico N. Determination of atazanavir in human plasma by high-performance liquid chromatography with UV detection. J. Chromatogr. Sci. 2008, 46:485-489.
9. Colombo S., Guignard N., Marzolini C., Telenti A., Biollaz J., Decosterd L.A. Determination of the new HIV-protease inhibitor atazanavir by liquid chromatography after solid-phase extraction. J. Chromatogr. B: Biomed. Sci. Appl. 2004, 810:25-34.
10. Loregian A., Pagni S., Ballarin E., Sinigalia E., Parisi S.G., Palu G. Simple determination of the HIV protease inhibitor atazanavir in human plasma by high-performance liquid chromatography with UV detection. J. Pharm. Biomed. Anal. 2006, 42:500-505.
11. Schuster A., Burzawa S., Jemal M., Loizillon E., Couerbe P., Whigan D. Quantitative determination of the HIV protease inhibitor atazanavir (BMS-232632) in human plasma by liquid chromatography-tandem mass spectrometry following automated solid-phase extraction. J. Chromatogr. B: Biomed. Sci. 2003, 788:377-386.
12. Sparidans R.W., Dost F., Crommentuyn K.M.L., Huitema A.D.R., Schellens J.H.M., Beijnen J.H. Liquid chromatographic assay for the protease inhibitor atazanavir in plasma. Biomed. Chromatogr. 2006, 20:72-76.
13. Dailly E., Raffi F., Jolliet P. Determination of atazanavir and other antiretroviral drugs (indinavir, amprenavir, nelfinavir and its active metabolite M8, saquinavir, ritonavir, lopinavir, nevirapine and efavirenz) plasma levels by high performance liquid chromatography with UV detection. J. Chromatogr. B: Biomed. Sci. Appl. 2004, 813:353-358.
14. Dickinson L., Robinson L., Tjia J., Khoo S., Back D. Simultaneous determination of HIV protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J. Chromatogr. B: Biomed. Sci. Appl. 2005, 829:82-90.
15. Notari S., Bocedi A., Ippolito G., Narciso P., Pucillo L.P., Tossini G., Donnorso R.P., Gasparrini F., Ascenzi P. Simultaneous determination of 16 anti-HIV drugs in human plasma by high-performance liquid chromatography. J. Chromatogr. B: Biomed. Sci. Appl. 2006, 831:258-266.
16. Poirier J.M., Robidou P., Jaillon P. Simple and simultaneous determination of the HIV-protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir plus M8 nelfinavir metabolite and the nonnucleoside reverse transcriptase inhibitors efavirenz and nevirapine in human plasma by reversed-phase liquid chromatography. Ther. Drug Monit. 2005, 27:186-192.
17. Quaranta S., Woloch C., Paccou A., Giocanti M., Solas C., Lacarelle B. Validation of an electrospray ionization LC-MS/MS method for quantitative analysis of raltegravir, etravirine, and 9 other antiretroviral agents in human plasma samples. Ther. Drug Monit. 2009, 31:695-702.
18. Rezk N.L., Crutchley R.D., Yeh R.F., Kashuba A.D.M. Full validation of an analytical method for the HIV-protease inhibitor atazanavir in combination with 8 other antiretroviral agents and its applicability to therapeutic drug monitoring. Ther. Drug Monit. 2006, 28:517-525.
19. Takahashi M., Yoshida M., Oki T., Okumura N., Suzuki T., Kaneda T. Conventional HPLC method used for simultaneous determination of the seven HIV protease inhibitors and nonnucleoside reverse transcription inhibitor efavirenz in human plasma. Biol. Pharm. Bull. 2005, 28:1286-1290.
20. Verbesselt R., Wijngaerden E., de Hoon J. Simultaneous determination of 8 HIV protease inhibitors in human plasma by isocratic high-performance liquid chromatography with combined use of UV and fluorescence detection: amprenavir, indinavir, atazanavir, ritonavir, lopinavir, saquinavir, nelfinavir and M8-nelfinavir metabolite. J. Chromatogr. B: Biomed. Sci. Appl. 2007, 845:51-60.
21. Weller D.R., Brundage R.C., Balfour H.H., Vezina H.E. An isocratic liquid chromatography method for determining HIV non-nucleoside reverse transcriptase inhibitor and protease inhibitor concentrations in human plasma. J. Chromatogr. B: Biomed. Sci. Appl. 2007, 848:369-373.
22. D'Avolio A., Baietto L., Siccardi M., Sciandra M., Simiele M., Oddone V., Bonora S., Di Perri G. An HPLC-PDA method for the simultaneous quantification of the HIV integrase inhibitor raltegravir, the new nonnucleoside reverse transcriptase inhibitor etravirine, and 11 other antiretroviral agents in the plasma of HIV-infected patients. Ther. Drug Monit. 2008, 30:662-669.
23. D'Avolio A., Siccardi M., Sciandra M., Baietto L., Bonora S., Trentind L., Di Perri G. HPLC-MS method for the simultaneous quantification of the new HIV protease inhibitor darunavir, and 11 other antiretroviral agents in plasma of HIV-infected patients. J. Chromatogr. B: Biomed. Sci. 2007, 859:234-240.
24. Elens L., Veriter S., Di Fazio V., Vanbinst R., Boesmans D., Wallem-Acq P., Haufroid V. Quantification of 8 HIV-protease inhibitors and 2 nonnucleoside reverse transcriptase inhibitors by ultra-performance liquid chromatography with diode array detection. Clin. Chem. 2009, 55:170-174.
25. Trudnows R.J., Rico R.C. Specific gravity of blood and plasma at 4°C and 37°C. Clin. Chem. 1974, 20:615-616.
26. US Food and Drug Administration, Guidance for Industry: Bioanalytical Method Validation, 2001, Last accessed on 02/11/2008. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070107.pdf.
27. Rudzki P.J., Les A. Application of confidence intervals to bioanalytical method validation-drug stability in biological matrix testing. Acta Pol. Pharm. 2008, 65:743-747.
28. Nowatzke W., Woolf E. Best practices during bioanalytical method validation for the characterization of assay reagents and the evaluation of analyte stability in assay standards, quality controls, and study samples. AAPA J. 2007, 9:E117-E122.
29. Scifinder Scholar, 2007, Predicted properties of atazanavir, registry no. 198904-31-3, 2009.
30. Scifinder Scholar, 2007, Predicted properties of diazepam, registry no. 439-14-5, 2009.
31. Almeida A.M., Castel-Branco M.M., Falcao A.C. Linear regression for calibration lines revisited: weighting schemes for bioanalytical methods. J. Chromatogr. B: Biomed. Sci. Appl. 2002, 774:215-222.
32. Bristol-Myers Squibb Company, Reyataz® package insert, 2006, Last accessed on 12/06/2008. http://packageinserts.bms.com/pi/pi_reyataz.pdf.